THE BIOLOGICAL ACTIVITY OF PLANT-DERIVED ANTI-HER2 RECOMBINANT ANTIBODIES

Pharmaceuticals derived from plants, have become one of the leading commercial directions in modern biotechnology. The benefits that offer these technologies, cannot be matched with any other modern technology for producing drugs from recombinant proteins. Main advantages of plant technologies for production of proteins are easy scalability, efficiency, bio-safety, ease of cultivation and collection of biological material. This approach promises to be the most perspective for production of a wide range of drug substances and vaccines. In current investigation we have analyzed in vitro and in vivo biological activity of plant-derived anti-HER2 recombinant antibodies - phytotrastuzumab. Phytotrastuzumab and trastuzumab have similar activity in grows suppression of breast cancer cells overexpressing HER2 in-vitro and were active in suppression of xenografted tumors SK-BR-3 in-vivo.

HER2, рак молочной железы, рекомбинантные антитела, экспрессия в растениях, HER2, breast cancer, recombinant antibodies, plant-derived proteins

1. Афанасьева Д.А., Барышникова М.А., Соколова З.А., Косорукое В.С. Разработка липосомальной конструкции, содержащей лизат опухолевых клеток // Российский биотерапевтический журнал. - 2013. -Т. 12, № 2. - С. 5.

2. Зангиева М.Т., Игнатьева Е.В., Косорукое В.С. Оценка эффективности включения доксорубицина в иммунолипосомы, направленные против HER2 рецептора // Российский биотерапевтический журнал. - 2013. - Т. 12, № 2. - С. 31.

3. Соколова Т.М., Кособокова Е.Н., Шувалов А.Н. и др. Активность генов системы интерферона в клетках аденокарциномы толстого кишечника НСТ-116: регуляция рекомбинантными интерферонами-альфа-2 из бактериальных и растительных продуцентов // Российский биотерапевтический журнал. -2013. - Т. 12. - № 3. - С. 39-44.

4. Трещалина Е.М., Жукова О. С., Герасимова Г.К. и др. Методические указания по изучению противоопухолевой активности фармакологических веществ. - В кн.: Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ/под общей ред. член-корр.РАМН проф. Р.У.Хабриева.-2 изд., перераб. и доп. - М.: ОАО изд. «Медицина», 2005. - C. 637-51.

5. Arntzen C.J. Using tobacco to treat cancer // Science. - 2008. - 321. - P. 1052-3.

6. De Muynck B., Navarre C., Boutry M. Production of antibodies in plants: status after twenty years // Plant Biotechnol J. - 2010. - P. 529-63.

7. Galeffi P., Lombardi A., Donato MD. et al. Expression of single-chain antibodies in transgenic plants // Vaccine. - 2005. - 15. - P. 1823-7.

8. Gijsen M., King P., Perera T. et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 Herceptin in breast cancer // PLoS Biol. - 2010. - 8(12). - e1000563.

9. Giritch A., Marillonnet S., Engler C. et al. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors // Proc Natl Acad Sci USA. - 2006. - 103. - P. 14701-6.

10. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice // N Engl J Med. - 2007. - 357 -P. 39-51.

11. Hudziak R.M., Lewis G.D., Winget M. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor // Mol Cell Biol. - 1989. - 3. - P. 1165-72.

12. Ko K., Steplewski Z., Glogowska M., Koprowski H. Inhibition of tumor growth by plant-derived mAb // Proc Natl Acad Sci USA. - 2005. - 102. - P. 7026-30.

13. Komarova T.V., Baschieri S., Donini M. et al. Transient expression systems for plant-derived biopharmaceuticals // Expert Rev Vaccines. - 2010. - 9. - P. 859-76.

14. Komarova T.V., Kosorukov V.S., Frolova O.Y. et al. Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth // PLoS ONE. - 2011. - 6. - Iss. 3. - e17541.

15. Lai H., Engle M., Fuchs A. et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice // Proc Natl Acad Sci USA. - 2010. - 107. - P. 2419-24.

16. Lie'nard D., Sourrouille C., Gomord V., Faye L. Pharming and transgenic plants // Biotechnol Annu Rev. -2007. - 13. - P. 115-47.

17. Ma J.K - C. The production of recombinant pharmaceutical proteins in plants // Nat. Rev. Genet. - 2003. -4. - P. 794-805.

18. McCormick A.A., Reddy S., Reinl S.J., Cameron T.I., Czerwinkski D.K., et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin’s lymphoma: safety and immunogenicity in a phase I clinical study // Proc Natl Acad Sci USA. - 2008. - 105. - P. 10131-6.

19. Mett V., Farrance C.E., Green B.J., Yusibov V. Plants as biofactories // Biologicals. -2008. - 36. - P. 354-8.

20. Pegram M., Hsu S., Lewis G. et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers // Oncogene. - 1999. - 18. - P. 2241-51.

21. Piccart-Gebhart M.J., Procter M., Leyland-Jones B. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer // N Engl J Med. - 2005. - 353. - P. 1659-72.

22. Pujol M., Gavilondo J., Ayala M. et al. Fighting cancer with plant-expressed pharmaceuticals // Trends Biotechnol. - 2007. - 10. -P. 455-9.

23. Raskin I., Ribnicky D.M., Komarnytsky S. et al. Plants and human health in the twenty-first century // Trends Biotechnol. - 2002. - 20. - P. 522-31.

24. Semenyuk E.G., Stremovskiy O.A., Edelweiss E.F. et al. Expression of single-chain antibody-barstar fusion in plants // Biochimie. -2007. - 89. - P. 31-8.

25. Slamon D.J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 // N Engl J Med. - 2001. - 344. - P. 783-92.